In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on Regeneron (REGN – Research Report), with a price ...

All three major averages (DJI, GSPC, IXIC) opened Wednesday's trading session in the red, weighed down by escalating trade ...

Regeneron Pharmaceuticals's REGN short percent of float has risen 26.83% since its last report. The company recently reported that it has 3.25 million shares sold short, which is 3.12% of all regular ...

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Regeneron (REGN) to $1,081 from $1,150 and keeps an Overweight rating ...

The stock's rise snapped a four-day losing streak.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Phathom Pharmaceuticals (PHAT – Research ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

The S&P 500 Index ($SPX) (SPY) today is up +0.64%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.29%, and the Nasdaq ...

The blue-chip Dow Jones was cautiously higher at the opening bell on Wednesday as Donald Trump's tit-for-tat tariff war with ...

2-Year U.S. Treasury Note Continuous Contract $103.480-0.453-0.44% 5-Year U.S. Treasury Note Continuous Contract $107.609-0.922-0.85% 10-Year U.S. Treasury Note Continuous Contract $110.297-1.172 ...

Vertex Pharmaceuticals Inc. $483.32 10.95 2.32% ...